ux/ui samples • kenny rupp interactive designer · • ux/ui samples • kenny rupp interactive...

• UX/UI SAMPLES •

KENNY RUPP INTERACTIVE DESIGNER

TO ATTENDu visit www.NULOJIX.com

u click on the title of the (REMS webinar session-title TBD) link

u select the appropriate link for that day

ON-DEMANDYou also have the option to view the video format of this webinar available 24/7 on www.NULOJIX.com/xxx.

SESSIONS BY-APPOINTMENTIf none of these times or dates fit into your schedule, the NULOJIX team will work with you to schedule a live session for you and your colleagues. Please call (XXX) YYY-ZZZZ or email [email protected] with your name, address, email address, and institution name.

We look forward to the opportunity to provide you with timely and relevant information that will be useful in your clinical practice.

NULOJIX™ (belatacept) Risk Evaluation and Mitigation Strategy (REMS)Webinars

You’re invited to

An interactive seminar that brings important information directly to you and your practice.

SCHEDULED SESSIONS All sessions begin at 12:00pm ET

Additional scheduled sessions available (FPO):u December 20, 2011

u March 20, 2012

u September 18, 2012

u March 19, 2013

u September 24, 2013

u March 25, 2014

24

31

S M T W T F SMAY

S M T W T F S

5

12

19

26

JULY

7

14

21

28

S M T W T F SJUNE

9

23

AUGUST S M T W T F S

6

20

SEPTEMBER S M T W T F S

Please join us for an interactive webinar program that focuses on safety concerns with NULOJIX™ (belatacept) and approaches to minimize and mitigate these risks. This program is part of a Risk Evaluation and Mitigation Strategy (REMS) program for NULOJIX.

The REMS webinar will include a 10-minute presentation followed by an interactive Q&A session.

The objective of the NULOJIX REMS is to communicate the increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS), and serious infections, including progressive multifocal leukoencephalopathy (PMS), in order to help inform appropriate benefit-risk decisions when healthcare providers (HCPs) are considering treatment with NULOJIX and throughout treatment. The goals of the NULOJIX REMS include:

u To inform HCPs of the increased risk of PTLD, predominantly in the CNS, associated with NULOJIX

u To inform HCPs of the increased risk of PML, a CNS infection, associated with NULOJIX

u To inform patients of the serious risks associated with NULOJIX

The NULOJIX Webcast series is sponsored by Bristol-Myers Squibb. The programs are not CME activities.

NULOJIXTM (belatacept) is indicated for prophylaxis of kidney rejection in adult patients (18 years of age and older)

receiving renal transplants. NULOJIX has been used in combination with an interleukin-2 (IL-2) receptor antagonist,

a mycophenolic acid (MPA), and corticosteroids. Please see IMPORTANT SAFETY INFORMATION, including boxed

WARNINGS regarding PTLD, for NULOJIX.

Important Safety InformationRISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD):r NULOJIX-treated patients are at an increased risk for developing PTLD, specifically involving the CNS

— The incidence of PTLD was higher in NULOJIX-treated patients (14/498;1.5%) than in cyclosporine-treated patients (2/476;0.4%) in the Phase 2 and 3 studies (3 Studies)

— NULOJIX-treated transplant recipients studied in the 2 clinical trials who were EBV seronegative were at an increased risk for PTLD compared with those who were EBV positive (7/96; 7.3% vs 6/805: 0.75%, respectively)

— 2 cases of PTLD were reported in an ongoing liver transplant trial. The safety and efficacy of NULOJIX has not been established in liver transplant patients

r Physicians should consider PTLD in the differential diagnosis in patients reporting new or worsening neurological, cognitive or behavioral signs or symptoms

r As the total burden of immunosuppression is a risk factor for PTLD, higher than the recommended doses or more frequent dosing of NULOJIX and concomitant immunosuppressive agents should be avoided

r Other known risk factors for PTLD include cytomegalovirus (CMV) infection and the use of T-cell-depleting therapies. CMV prophylaxis is recommended for at least 3 months after transplantation

MANAGEMENT OF IMMUNOSUPPRESSION:r Only physicians experienced in management of systemic immunosuppressive therapy in transplantation should prescribe NULOJIX

— Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources

RISK FOR OTHER MALIGNANCIES:r In addition to PTLD, patients on immunosuppressive therapy are at increased risk of malignancies, including the skin. Exposure to

sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor

RISK OF SERIOUS INFECTIONS:r Patients treated with NULOJIX are at increased risk for developing serious infections that may lead to serious outcomes including

death. Reported infections include:— Cases of tuberculosis (TB) - Patients should be evaluated for TB and tested for latent infection before NULOJIX use - Treatment for latent infection should be initiated prior to NULOJIX use — Bacterial, viral, and opportunistic infections including fungal and protozoal infections

RISK FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML):r PML is a rare, often rapidly progressive and fatal, opportunistic infection of the CNS caused by the JC virusr 2 cases of PML (1 in a renal transplant recipient and 1 in a liver transplant recipient) were reported in patients receiving NULOJIX at

doses higher/more frequently than the recommended regimen along with mycophenolate mofetil (MMF) and corticosteroids r As PML has been associated with high levels of overall immunosuppression, the recommended doses of NULOJIX and concomitant

immunosuppressives, including MMF or MPA should not be exceededr When patients exhibit clinical symptoms suggestive of PML, consider radiographic evaluation by MRI, cerebrospinal fluid evaluation by

PCR for JC virus, and consultation by a specialistr If PML is diagnosed, reduction or withdrawal of immunosuppression including NULOJIX is recommended taking into account the risk to

the graft

LATENT VIRUS INFECTIONS:r Patients receiving immunosuppressants, including NULOJIX, are at increased risk for opportunistic infections including JC virus and

BK virusr Cases of BK virus associated nephropathy (BKVAN) and JC virus associated PML have been observed in patients receiving NULOJIX r BKVAN is serious and can lead to deteriorating renal function and graft loss r Monitoring may help detect patients at risk for BKVAN. Reductions in immunosuppression should be considered for patients who

develop evidence of BKVANImmunizations: Patients on NULOJIX should not receive live vaccinesPregnancy: NULOJIX should be used in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetusNursing Mothers: Nursing mothers should be informed of the risk/benefit of continued breast-feeding or discontinuation of the drugInfusion Reactions: Acute infusion-related reactions (occurring within 1 hour of infusion) occurred in 5.7% of patients treated with a higher than recommended dosage and 4.4% of patients treated with the recommended clinical dosage. Most frequently reported reactions were hypotension, hypertension, flushing, and headacheProteinuria: —The incidence of proteinuria (2+ on urine dipstick) was higher in NULOJIX-treated patients (31%) than in cyclosporine-treated patients (26%) in

standard criteria donors —The incidence of proteinuria (2+ on urine dipstick) was higher in NULOJIX-treated patients (36%) than in cyclosporine-treated patients (31%) in

extended criteria donors —The clinical significance of this increase in early proteinuriaCommonly observed adverse reactions: By Year 2 (≥20%) reported by patients treated with NULOJIX were anemia, diarrhea, urinary tract infection, constipation, peripheral edema, hypertension, graft dysfunction, pyrexia, nausea, vomiting, cough, and hyperkalemia.

NULOJIX is available as 250 mg lyophilized powder for intravenous infusion.

FPO

FPO

Click here to see the Full Prescribing Information for NULOJIX, including Boxed WARNINGS.

©2010 Bristol-Myers Squibb 721US11EM01602 4/11

721US11EM01602_REMS_Webinar_Email_v1.indd 1 4/1/11 2:47 PM

446US09WA00144BMS Medical Information Online 02/01

1

BROWSER PAGE TITLE:Post Login Home Page with PI Dropdown

NOTES:

Two sets of design comps

for the search user interface

pages are part of this

submission and include

the addition of FORXIGA™

(dapagliflozin). Only 1 of

these options will move

forward.

The first set of pages

regarding the search user

interface are currently being

implemented for a January

launch date (Option 1). These

updates have already been

approved (446US09WA00141)

and are in their final stages. If

there are any delays, Option

2 comps will be used as a

contingency. Option 2 comps

are based off of the current

live MIO site.

All pages with content

changes have been shown.

Added FORXIGATM (dapagliflozin)

to PI widget and it will link to

http://packageinserts.bms.

com/pi/pi_forxiga.pdf

Global: Replaced TM with ® for

Onglyza

https://www.bmsmedinfo.com/protected/search.aspxOption 1


2

BROWSER PAGE TITLE:Search Page (default state)

NOTES:Search Page (default state)



3

BROWSER PAGE TITLE:Search Page (options shown)

NOTES:

Added FORXIGATM

(dapagliflozin) to the drop

down list



4

BROWSER PAGE TITLE:Product Information(By Brand)

NOTES:

Added FORXIGATM

(dapagliflozin) to Product

Information page

—hyperlink for PI links to





5

BROWSER PAGE TITLE:Product Information(By generic)

NOTES:

Added (dapagliflozin)

FORXIGATM to Product

Information page

—hyperlink for PI links to





6

BROWSER PAGE TITLE:Search Page (MIRF overlay,

default state)

NOTES:

eMIRF form will display when the

user clicks on the “Ask a Medical

Information Professional” tab or

link on the search page.



7

BROWSER PAGE TITLE:Search Page (MIRF overlay with dropdown)

NOTES:

Added FORXIGATM

(dapagliflozin) to drop-down list


000000_OneBydureon Site_v03 11/12

1

HOME PAGE

SLIDER WIDGET IN UPPER RIGHT CORNER AUTOMATICALLY TRANSITIONS THROUGH CHOSEN IMAGES, BUT CAN BE NAVIGATION VIA THE PAGINATION “DOTS” AS WELL.

TABBED WIDGET ON THE BOTTOM RIGHT SHOWS “NEWS FLASH” UPON

ENTERING SITE


2

HOME PAGE ALT VIEW

DROP DOWN MENU STYLE SHOWN.

“FAVORITES” TAB IN WIDGET

HAS BEEN SELECTED.


3

HOME PAGE ALT VIEW

“QUICK LINKS” TAB IN

WIDGET HAS BEEN SELECTED.

THIS TAB HAS A VERTICAL

SCROLLING FEATURE.


4

BYDUREON INDICATION PAGE

WIDGETS STILL PRESENT.

INDICATION MENU HOVER

/ DROPDOWN MENU

FUNCTIONALITY SHOWN.


5

BYDUREON SUB PAGE

COLOR SCHEME IDENTIFIES

BRAND.

LEFT SIDE NAVIGATION NOW

AVAILABLE.


6

BYETTA INDICATION PAGE

NEW COLOR SCHEME

IDENTIFIES NEW BRAND.


INDICATION HOVER

/ DROPDOWN MENU



7

BYETTA SUB PAGE

NEW COLOR SCHEME



AVAILABLE.


8

BYETTA + BASAL INSULIN

INDICATION PAGE

NEW COLOR SCHEME



INDICATION HOVER

/ DROPDOWN MENU



9

BYETTA + BASAL INSULIN

SUB PAGE

NEW COLOR SCHEME



AVAILABLE.


10

CONTACT PAGE /

WHO’S WHO


11

CALENDAR PAGE

DEPICTS MONTHLY VIEW.

125147 Data Commons Website 06/25/12

1

Homepage (Option 1)


2

Search Functionality


3

Homepage (Option 2)


4

Interior Page - About


5

Links Menu


6

Resources Menu


7

Detailed View - Rollover Functionality


8

Access Rollover - Detailed View


9

Partners Rollover - Detailed View

ux/ui samples • kenny rupp interactive designer · • ux/ui samples • kenny rupp interactive...

Documents